ERBB2 and breast carcinoma: The indications for trastuzumab emtansine (TE), enfortumab vedotin (EV), brentuximab vedotin (BV), and polatuzumab vedotin (PV) are ErbB2-positive metabolic breast cancer, advanced urothelial cancer, Hodgkin’s lymphoma/analytical large cell lymphoma/peripheral T-cell lymphomas/mycosis fungoides, or diffuse large B-cell lymphoma.